The Food and Drug Administration (FDA) has granted Fast Track designation to OBX-115 for the treatment of metastatic, or locally advanced melanoma
Brian Park is a Staff Editor specializing in medical and healthcare topics. With a focus on dermatology, cancer therapy, and general medical research, Brian's work has been featured in various publications such as MPR - Medical Professionals Reference, Dermatology Advisor, and Cancer Therapy Advisor. He brings a wealth of knowledge and expertise to his articles, providing valuable insights for medical professionals and patients alike.